Breaking News

Tweet TWEET

Acura Pharmaceuticals' Universal Shelf Registration Statement Declared Effective

Acura Pharmaceuticals' Universal Shelf Registration Statement Declared Effective 
PALATINE, IL -- (Marketwire) -- 03/15/13 --  Acura Pharmaceuticals,
Inc. (NASDAQ: ACUR) today announced that its universal shelf
registration statement on Form S-3 was declared effective by the
Securities and Exchange Commission (SEC) today. 
The universal shelf registration statement permits the Company to
offer and sell, from time to time, on a continuous or delayed basis
in the future, up to $75 million of equity, debt or other types of
securities described in the shelf registration statement, or any
combination of such securities, in one or more future public
offerings. 
"We believe the shelf registration statement provides us with a
potential source of capital for corporate purposes, such as for
working capital and acquisitions," said Bob Jones, President and
Chief Executive Officer of Acura.  
If and when the Company offers any securities under the shelf
registration statement, the Company will prepare and make available a
prospectus supplement that includes the specific terms of the
securities being offered, the use of proceeds and other terms of the
offering.  
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any of these
securities in any state in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities law of any such state.  
About Acura Pharmaceuticals
 Acura Pharmaceuticals is a specialty
pharmaceutical company engaged in the research, development and
commercialization of product candidates intended to address
medication abuse and misuse, utilizing its proprietary AVERSION(R)
and IMPEDE(TM) technologies.  
In June 2011, the U.S. Food and Drug Administration approved
OXECTA(R) which incorporates the AVERSION(R) technology. The Company
has a development pipeline of additional AVERSION(R) technology
products including other opioids.  
In December, 2012 the Company commenced commercialization of
Nexafed(R) [pseudoephedrine hydrochloride (HCl)] a 30 mg
immediate-release abuse-deterrent decongestant. The next generation
pseudoephedrine tablet combines effective nasal congestion relief
with IMPEDE(TM) technology, a unique polymer matrix that 
disrupts the
conversion of pseudoephedrine into the dangerous drug,
methamphetamine.  
The trademark OXECTA(R) is owned by Pfizer Inc. 
Forward-Looking Statements
 Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forwarding-looking statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performance, or achievements expressed or implied by
such forward-looking results, performance, or achievements expressed
or implied by such forward-looking statements. Forward-looking
statements may include, but are not limited to, our ability to raise
capital under the shelf registration statement from the sale of our
securities, our and our licensee's ability to successfully launch and
commercialize our products and technologies including Oxecta(R)
Tablets and Nexafed(R) Tablets, the price discounting that may be
offered by Pfizer for Oxecta(R), our and our licensee's ability to
obtain necessary regulatory approvals and commercialize products
utilizing our technologies and the market acceptance of and
competitive environment for any of our products, the willingness of
wholesalers and pharmacies to stock Nexafed Tablets, expectations
regarding potential market share for our products and the timing of
first sales, our ability to enter into additional license agreements
for our other product candidates, our exposure to product liability
and other lawsuits in connection with the commercialization of our
products, the increased cost of insurance and the availability of
product liability insurance coverage, the ability to avoid
infringement of patents, trademarks and other proprietary rights of
third parties, and the ability of our patents to protect our products
from generic competition, our ability to protect and enforce our
patent rights in any paragraph IV patent infringement litigation, and
the ability to fulfill the FDA requirements for approving our product
candidates for commercial manufacturing and distribution in the
United States, including, without limitation, the adequacy of the
results of the laboratory and clinical studies completed to date, the
results of laboratory and clinical studies we may complete in the
future to support FDA approval of our product candidates and the
sufficiency of our development to meet over-the-counter, or OTC,
Monograph standards as applicable, the adequacy of the development
program for our product candidates, including whether additional
clinical studies will be required to support FDA approval of our
product candidates, changes in regulatory requirements, adverse
safety findings relating to our product candidates, whether the FDA
will agree with our analysis of our clinical and laboratory studies
and how it may evaluate the results of these studies or whether
further studies of our product candidates will be required to support
FDA approval, whether or when we are able to obtain FDA approval of
labeling for our product candidates for the proposed indications and
will be able to promote the features of our abuse discouraging
technologies, whether our product candidates will ultimately deter
abuse in commercial settings and whether our Impede technology will
disrupt the processing of pseudoephedrine into methamphetamine. In
some cases, you can identify forward-looking statements by terms such
as "may," "should," "could," "would," "expects," "plans,"
"anticipates," "believes," "estimates," "projects," Predicts,"
"potential" and similar expressions intended to identify
forward-looking statements. These statements reflect our current
views with respect to future events and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you
should not place undue reliance on these forward-looking statements.
We discuss many of these risks in greater detail in our filings with
the Securities and Exchange Commission. 
Contact: 
for Acura Investor Relations
investors@acurapharm.com
847-705-7709 
for Acura Media Relations
pr@acurapharm.com
847-705-7709 
 
 
Press spacebar to pause and continue. Press esc to stop.